

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

Brilliant Violet 605(TM) anti-human CD8

RRID:AB_2566513

Type: Antibody

Proper Citation

BioLegend Cat# 344742, RRID:AB_2566513

Antibody Information

URL: http://antibodyregistry.org/AB_2566513

Proper Citation: BioLegend Cat# 344742, RRID:AB_2566513

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2566513

Vendor: BioLegend

Catalog Number: 344742

Alternative Catalog Numbers: 344741

Record Creation Time: 20250820T035327+0000

Record Last Update: 20250820T172724+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liu X, et al. (2026) Distinct Inflammatory Cytotoxic T Lymphocyte Populations Mediate PD-1 Blockade-Induced Immune-Related Adverse Events in Multiple Organs. *Cancer research*, 86(15), 3720.

Chen L, et al. (2026) Bilirubin mitigates ischemic white matter injury by targeting transferrin-receptor-mediated B cell immunometabolism. *Cell reports*, 45(6), 117398.

Gramatica A, et al. (2025) EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes. *Cell reports*, 44(5), 115652.

Cimen Bozkus C, et al. (2025) T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome. *iScience*, 28(8), 113044.

Zhu M, et al. (2024) Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway. *Cell reports*, 43(4), 114065.

Giovenzana A, et al. (2024) Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesity. *iScience*, 27(3), 109032.

Li Y, et al. (2024) SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. *Science translational medicine*, 16(731), eadk1599.

Si X, et al. (2024) Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. *Cell metabolism*, 36(1), 176.

Bopp L, et al. (2024) Glutamine promotes human CD8+ T cells and counteracts imiquimod-induced T cell hyporesponsiveness. *iScience*, 27(5), 109767.

Abhiraman GC, et al. (2023) A structural blueprint for interleukin-21 signal modulation. *Cell reports*, 42(6), 112657.

Silver AB, et al. (2023) An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2. *Cell reports. Medicine*, 4(11), 101289.

Yan C, et al. (2023) Exhaustion-associated cholesterol deficiency dampens the cytotoxic arm of antitumor immunity. *Cancer cell*, 41(7), 1276.

Reuschl AK, et al. (2022) HIV-1 Vpr drives a tissue residency-like phenotype during selective infection of resting memory T cells. *Cell reports*, 39(2), 110650.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. *Cell*, 185(8), 1414.

VanDyke D, et al. (2022) Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection. *Cell reports*, 41(3), 111478.

Glassman CR, et al. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. *Cell*, 184(4), 983.

Xie G, et al. (2021) Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4⁺ T cell subsets in vivo. *Cell reports*, 35(4), 109038.